-
SP2509 and the Translational Logic of LSD1 Targeting
2026-08-24
SP2509 offers a mechanism-led framework for investigating Lysine-specific demethylase 1 antagonism in acute myeloid leukemia. By inhibiting LSD1 catalytic activity and disrupting its association with the CoREST complex, SP2509 links chromatin remodeling to H3K4 trimethylation, tumor suppressor gene activation, apoptosis, and differentiation. This thought-leadership article examines how researchers can convert those findings into rigorous translational workflows, how combination strategies may be prioritized, and why evidence from broader cancer epigenetics should inform—without overextending—AML research hypotheses.
-
Pregnenolone Carbonitrile: Assay Reliability
2026-08-23
Learn how Pregnenolone Carbonitrile (SKU C3884) can support controlled PXR, cytochrome P450, liver fibrosis, and cell-assay workflows. This scenario-based guide focuses on solvent compatibility, protocol design, interpretation of tissue-specific responses, and practical product selection.
-
miR-3180 Rewires Lipid Metabolism in HCC
2026-08-22
Hong et al. identify miR-3180 as a regulatory link between fatty-acid synthesis and uptake in hepatocellular carcinoma (HCC). By connecting SCD1 and CD36 to tumor growth and metastasis, the study provides a mechanistic framework for interpreting lipid-metabolic control of HCC and suggests how tissue-based assays can support biomarker evaluation.
-
Deferiprone: A Precision Tool for Iron Stress
2026-08-21
Deferiprone connects ferric-ion chelation with metabolic, inflammatory, and translational research questions, offering a practical framework for studying iron stress across enterocyte and disease models.
-
WZ4003: From NUAK Mechanism to Translational Strategy
2026-08-20
WZ4003 is a selective NUAK1/2 inhibitor that connects kinase mechanism with actionable assays in cancer research and tau biology. This thought-leadership guide explains how to validate target engagement, interpret phenotypes, and translate findings across models without overstating preclinical evidence.
-
2'3'-cGAMP: From STING Ligand to Assay Design
2026-08-20
Discover how 2'3'-cGAMP (sodium salt) connects direct STING activation with delivery-aware immunology assays. This article translates recent photodynamic immunotherapy findings into practical controls, handling decisions, and interpretation strategies.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-08-19
The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its data connect bladder-restricted delivery with tumor-suppressor restoration, cell-cycle inhibition, DNA-damage accumulation, and tumor suppression in an orthotopic model, while also identifying important translational limitations.
-
RG108: DNA Methyltransferase Inhibitor Workflow
2026-08-19
RG108 is a non-nucleosidic DNA methyltransferase inhibitor for testing DNA methylation changes without relying on covalent enzyme trapping or DNA incorporation. This guide translates its biochemical profile and rat pharmacokinetic evidence into practical cell-based, gene-reactivation, and exposure-monitoring workflows.
-
Measuring Cancer Drug Responses Beyond Cell Viability
2026-08-18
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. By separating growth inhibition from cell killing, the work provides a more interpretable framework for comparing drug effects, timing, and experimental readouts in vitro.
-
RG108: Designing Better DNMT Inhibition Studies
2026-08-18
RG108 is a DNA methyltransferase inhibitor suited to dissecting the relationship between enzymatic inhibition, DNA demethylation, and gene reactivation. This guide translates biochemical, cellular, and rat pharmacokinetic evidence into practical assay and study-design decisions.
-
In Vitro Drug Response Metrics in Cancer
2026-08-17
Hannah Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central contribution is a framework for separating growth inhibition from cell killing, improving interpretation of drug activity and experimental design in cancer research.
-
One-step TUNEL Cy3 Apoptosis Detection Kit Guide
2026-08-17
Build reproducible DNA fragmentation workflows for cultured cells, organoids, and tissue sections with Cy3-based fluorescence. This guide connects practical TUNEL optimization to colorectal cancer drug-response studies and shows how to distinguish useful apoptotic signals from technical artifacts.
-
Cathepsin B inhibitor CA-074: Practical Lab Guide
2026-08-16
CA-074 (SKU A1926) is a selective cathepsin B inhibitor for testing protease-dependent biochemical and cellular phenotypes. This guide covers preparation, controls, selectivity checks, and troubleshooting; it should not be treated as evidence of efficacy in a particular disease model or as a substitute for direct target-engagement validation.
-
Hexetidine (NSC-17764) Biofilm Assay Workflows
2026-08-15
Hexetidine (NSC-17764) supports practical MIC, kill-kinetics, oral biofilm, and device-associated infection studies across bacteria and Candida albicans. This guide connects concentration selection with biofilm age, solvent control, recovery testing, and translational limits for more reproducible antimicrobial experiments.
-
SGI-1027–Everolimus Synergy in Renal Cancer
2026-08-14
The reference study identifies SGI-1027 as an inducer of vacuolation and methuosis in renal cancer cells and shows that it cooperates with everolimus. The combination promotes lysosomal membrane permeability, apoptosis, and GSDME-dependent pyroptosis, providing a mechanistic framework for studying strategies against everolimus-resistant renal cell carcinoma.